论文部分内容阅读
目的:分析多形性黄色星型细胞瘤(PXA)的临床、影像及病理特点，探讨其有效治疗方法。方法:回顾性纳入福建医科大学附属第一医院神经外科自2012年7月1日至2019年12月1日收治的25例颅内PXA患者，分析其临床表现、影像学特征、病理学特征及治疗方式，并随访研究其预后。结果:25例患者中首发症状以头痛(12例)及癫痫(8例)最为常见。肿瘤位置多见于顶叶(8例)，其次为颞叶(6例)、额叶(6例)。病理结果中，世界卫生组织(WHO)分级Ⅱ级患者肿瘤细胞增殖核抗原(Ki-67)平均阳性率为6.4%，P53平均阳性率21.2%；WHO分级Ⅲ级患者的Ki-67平均阳性率为22.2%，P53平均阳性率为48.3%。15例检测突触素(Syn)蛋白患者中阳性12例。20例患者术后随访31个月，存活19例，9例未见肿瘤复发或残留，其中WHO Ⅱ级8例，WHO Ⅲ级1例。结论:病理结果在PXA诊断中发挥重要作用，WHO Ⅱ级患者预后明显优于Ⅲ级患者。“,”Objective:To analyze the clinical, imaging and pathological characteristics of pleomorphic xanthoastrocytoma (PXA), and to explore the effective treatment of PXA.Methods:A total of 25 patients with PXA admitted to our hospital from July 1, 2012 to December 1, 2019 were chosen in our study. Their clinical manifestations, imageology features, pathology features, treatments, and prognoses were retrospectively analyzed.Results:Headache (n n=12) and epilepsy (n n=8) were the most common first symptoms in 25 patients. The tumors in 8 patients were located in the parietal lobe, 6 were in the temporal lobe, and 6 were in the frontal lobe. Among the pathological results, the average positive rate of cell proliferation antigen Ki-67 and P53 in patients with WHO grading II was 6.4% and 21.2%, respectively; the average positive rate of Ki-67 and P53 in patients with WHO grading III was 22.2% and 48.3%, respectively. Synaptophysin protein was confirmed in 12 of the 15 patients. Twenty patients were followed up for 31 months after surgery; 19 survived; 9 had no tumor recurrence or residue, including 8 with WHO grading II and one with WHO grading III.n Conclusion:Pathological result play an important role in PXA diagnosis; the prognosis of patients with WHO grading II is obviously better than that of patients with WHO grading III.